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Damage to joints through injury or disease can result in cartilage loss, which if left
untreated can lead to inflammation and ultimately osteoarthritis. There is currently
no cure for osteoarthritis and management focusses on symptom control. End-stage
osteoarthritis can be debilitating and ultimately requires joint replacement in order to
maintain function. Therefore, there is growing interest in innovative therapies for cartilage
repair. In this systematic literature review, we sought to explore the in vivo evidence for
the use of human Mesenchymal Stem Cell-derived Extracellular Vesicles (MSC-EVs) for
treating cartilage damage. We conducted a systematic literature review in accordance
with the PRISMA protocol on the evidence for the treatment of cartilage damage
using human MSC-EVs. Studies examining in vivo models of cartilage damage were
included. A risk of bias analysis of the studies was conducted using the SYRCLE tool.
Ten case-control studies were identified in our review, including a total of 159 murine
subjects. MSC-EVs were harvested from a variety of human tissues. Five studies induced
osteoarthritis, including cartilage loss through surgical joint destabilization, two studies
directly created osteochondral lesions and three studies used collagenase to cause
cartilage loss. All studies in this review reported reduced cartilage loss following treatment
with MSC-EVs, and without significant complications. We conclude that transplantation
of MSC-derived EVs into damaged cartilage can effectively reduce cartilage loss in
murine models of cartilage injury. Additional randomized studies in animal models that
recapitulates human osteoarthritis will be necessary in order to establish findings that
inform clinical safety in humans.
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INTRODUCTION
Damage to joints through injury or disease can result in cartilage loss, which if left untreated can
lead to inflammation and ultimately osteoarthritis (OA) (Davies-Tuck et al., 2008). OA affects
up to three out of 10 people over the age of 60 years (Woolf and Pfleger, 2003), and this is
projected to increase substantially (Turkiewicz et al., 2014). There is currently no cure for OA
and management is focused on symptom control (Mcalindon et al., 2014). Furthermore, the
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search for Disease Modifying Osteoarthritis Drugs (DMOAD)
has not been fruitful, and there are no approved DMOADs.
End-stage OA can be severely debilitating and ultimately requires
joint replacement in order to maintain function (Gillam et al.,
2013). Joint replacement is costly and carries perioperative
morbidity (Berstock et al., 2014) as well as unsatisfactory
outcomes (Nilsdotter et al., 2003). Therefore, there is a need for
innovative therapies to treat cartilage defects and in doing so,
prevent OA.
The established treatment of microfracture for focal cartilage
defects aims to encourage endogenous cells to repopulate areas
of cartilage loss, but this has demonstrated limited effectiveness
(Weber et al., 2018). A large number of studies have investigated
tissue engineering and cellular regenerative approaches to
treating cartilage defects (Negoro et al., 2018). Acellular
biomaterial scaffolds are costly to develop and implantation of
these scaffolds into cartilage defects exhibits a high failure rate
(Vindas Bolaños et al., 2017). Certain cell-based approaches such
as Autologous Chondrocyte Implantation (ACI) can be effective
but cause donor-site morbidity (Reddy et al., 2007; Bexkens et al.,
2017). Recently, there has been an increasing body of evidence to
support the use of Mesenchymal Stem Cells (MSCs) in cartilage
repair (Borakati et al., 2018).
MSCs are multipotent adult stromal cells that may be
derived from a number of tissues including bone marrow,
synovium, adipose, umbilical cord and dental pulp, and
so are readily available for autologous harvest (Fernandes
et al., 2018; Fabre et al., 2019). Ease of extraction and the
potential for ex vivo expansion make MSCs an attractive
option for tissue repair. To this end, studies have shown
the therapeutic potential of MSC transplantation in
promoting regeneration of tissues such as bone, cartilage,
and nerve (Katagiri et al., 2017; Freitag et al., 2019;
Masgutov et al., 2019). However, MSC transplantation is
not without risks. Certain studies have revealed potential
immunogenic complications related to repeated allogenic
transplantation of MSCs (Cho et al., 2008) and others have
reported possible tumorigenic properties (Beckermann
et al., 2008). There is also in vivo evidence to suggest
that, when transplanted in the presence of malignancy,
MSCs may increase the risk of metastasis (Karnoub et al.,
2007). Suboptimal engraftment and delocalization from the
target site create difficulty in maintaining sustained benefit
following transplantation, and suggest that observed long-
term benefits may not result from MSC differentiation alone
(Zwolanek et al., 2017).
Increasingly so, studies are focussing on the paracrine
function of MSCs as the predominant mechanism of their
regenerative effects (Linero and Chaparro, 2014; Xu et al.,
2016). MSC-derived extracellular vesicles (MSC-EVs) are gaining
interest as a cell-free therapeutic option for cartilage repair.
As part of MSC secretome, EVs are nanovesicles ranging from
10 nm to several micrometers that contain various components
including genetic material in the form of messenger RNA
(mRNA), microRNA (miRNA), lipids and bioactive proteins
(Di Vizio et al., 2012; Huang et al., 2017; Théry et al., 2018).
MSC-EVs are characterized by cell-surface expression of generic
EV markers such as CD9, CD81, CD82, TSG101, and Alix.
Transplantation of MSC-EVs may carry certain advantages over
cell-based therapies. Firstly, accurate quantification of number of
transplanted MSCs may be difficult and their effects could also
be less predictable than that of EVs within the recipient site,
potentially making outcomes of clinical trials less reproducible.
Production costs of EVs at a large scale could be lower than
that of MSCs (Cha et al., 2018). Furthermore, EVs exert
low potential for toxicity and immunogenicity with repeated
transplantation (Zhu X. et al., 2017; Saleh et al., 2019), and
therefore avoid the undesired immunogenic properties of MSCs
(Gu et al., 2015). As a cell-free therapy, MSC-EVs can be stored
by cryopreservation whereas MSCs cannot, and therefore have
greater potential as an off-the-shelf treatment option (Vlassov
et al., 2012).
Through mechanisms including direct receptor interaction,
membrane fusion, and internalization, EVs are able to influence
recipient cell behavior to promote a variety of effects relevant
to cartilage repair. In vitro evidence shows that MSC-EVs exert
anti-inflammatory effects through influencing IL-6 and TGF-β
secretion by dendritic cells. Furthermore, MSC-EVs are found
to contain miRNAs such as miR-21-5p which target the CCR7
gene for degradation (Reis et al., 2018) and non-coding RNA
that mediate an anti-inflammatory response (Fatima et al., 2017).
Co-culture of MSCs with chondrocytes is found to promote
matrix production and chondrocyte chondrogenesis in vitro, and
these effects appear to be EV-dependent (Kim et al., 2019). In
vitro studies also suggest that chondrocytes take-up MSC-EVs
that upregulate type II collagen production (Vonk et al., 2018).
Finally, results of recent ex vivo studies have suggested that
MSC-conditioned media is able to downregulate the expression
of genes that promote extra-cellular matrix degradation such
as MMP1, MMP13, and IL-1β in synovial explants (van Buul
et al., 2012) facilitating cartilage repair, suggesting a role for EVs
(Nawaz et al., 2018).
Recently, there has been increasing interest in the use of
MSC-EVs in cartilage repair and some systematic reviews have
examined the in vitro evidence for animal MSC-EVs. In this
systematic literature review, we sought to explore the in vivo
evidence for the use of human-derived MSC-EVs in murine
models of cartilage repair.
MATERIALS AND METHODS
The methods used to conduct this review were according to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement protocol (Moher et al., 2015).
We carried out a literature search on PubMed, Scopus, and
EmBase databases in January 2020, capturing articles starting
from conception. The following search strategy was applied:
(Mesenchymal stem cell OR MSC∗ OR Multipotent stromal
cell OR Multipotent stem cell OR Mesenchymal stromal cell)
AND (Extra-cellular vesicle OR extracellular vesicle OR EV∗
OR exosomal OR exosome) AND (osteoarthritis OR OA∗
OR osteochondral OR Cartilage). Following de-duplication,
exclusion criteria was applied to studies not written in or
translated into the English language. We excluded studies
that only performed in vitro experiments. Studies that did
not characterize or validate the cell populations as per the
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FIGURE 1 | Prisma flow diagram.
recommendations of the International Society for Cellular
Therapy (ISCT) for MSC were excluded (Witwer et al., 2019).
We included studies that examined the effects of human
MSC-derived exosomes, studies examining animal MSC-derived
exosomes were excluded. Studies that conducted characterization
of EVs in accordance with The International Society for
Extracellular Vesicles (ISEV) standards were included (Théry
et al., 2018). We included case-control studies, randomized
control trials, case series, and case reports with two or more
subjects. After removing duplicates, a total of 727 studies
underwent title screening (Figure 1). A total of 24 studies were
examined in full text. Ten studies were included in our review.
Quality assessment was carried out independently KR and
CM using the SYstematic Review Center for Laboratory animal
Experimentation (SYRCLE) tool (Hooijmans et al., 2014),
discrepancies in results were resolved by discussion.
RESULTS
MSC Characteristics
We identified 10 studies in our review, all of which were case-
control studies with murine subjects. MSCs were derived from
a variety of human tissue sources (Table 1). Four studies (Wang
et al., 2017), three by the same group, used MSCs derived from
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TABLE 1 | Method of MSC harvest and characterization.
References Source Cell harvest Cell treatment MSC characterization
Khatab et al. (2018) Human Heparinised femoral shaft bone marrow
aspirate
Cultured in minimal essential medium
alpha (α MEM), Fetal Calf Serum (FCS) and
Invitrogen to third passage
Trilineage differentiation, Flow cytometry:
CD73, CD90, CD105, CD166 +ve
Mao et al. (2018) Human Bone marrow aspirate from iliac crest Cultured in astandard Mesenchymal Stem
Cell (MSC) media and changed to
chondrogenic media from third passage
onwards. miR-92a-3p overexpressed in
one group
Trilineage differentiation, Flow cytometry:
CD11b, CD19, CD34, CD45, CD73,
CD90, CD105, and HLA-DR –ve
Tao et al. (2017) Human Synovial membrane tissue Cultured in standard MSC media to fifth
passage. miR-140-5p overexpressed in
one group
Trilineage differentiation, Flow cytometry:
CD44, CD73, CD90, CD105, CD151 +ve
Wang et al. (2017) Human Embryonic stem cell-derived MSCs
(obtained from third party)
Cultured in standard MSC media and cells
between fourth and seventh passage were
utilized
Trilineage differentiation, Flow cytometry:
CD73, CD90, CD105 +ve
Wu et al. (2019) Human Infrapatellar fat pad obtained following
total knee arthroplasty
Cultured in standard MSC media to
confluence and used at first passage
Flow Cytometry: CD44, CD73, CD90 +ve.
CD34, CD11b, CD19, CD45, HLA-DR
present at low levels
Zhang et al. (2016) Human Cleavage and blastocyst- stage embryonic
stem cells from in vitro fertilization
Cultured in standard MSC media. Further
details not stated
Trilineage differentiation, Flow cytometry:
CD105, CD24 +ve
Zhang et al. (2018) Human Immortalized E1-Myc 16.3 embryonic
stem cell-derived MSC
Cultured in standard MSC media and
passaged at 80% confluence until use.
Grown in defined media for 3 days prior to
exosome extraction
Trilineage differentiation, Flow cytometry:
CD29, CD44, CD90, CD105 +ve, CD34,
CD45, HLA-DR –ve
Zhang et al. (2019) Human Immortalized E1-Myc 16.3 embryonic
stem cell-derived MSC
Cultured in standard MSC media and
passaged at 80% confluence until use.
Grown in defined media for 3 days prior to
exosome extraction
Trilineage differentiation, Flow cytometry:
CD29, CD44, CD90, CD105 +ve, CD34,
CD45, HLA-DR –ve
Zhu Y. et al. (2017) Human Induced pluripotent stem cell-derived
MSC (iMSC) induced from human
umbilical cord iPS
Synovial MSC (sMSC) from humans
undergoing Anterior crucial efforts
ligament (ACL) reconstruction
iMSC: iPS cultured for 5 days in mTESR1
(Stemcell) and then cultured in standard
MSC media for 2 weeks. The cells were
then passaged every 5–7 days until a
fibroblastic morphology was adopted
sMSC: cultured in standard MSC media,
with media changed every 4 days
Trilineage differentiation Flow cytometry:
iMSC: CD29, CD44, CD73, CD90 +ve.
CD34, CD45, HLA-DR –ve
sMSC: CD44, CD73, CD90, CD166 +ve.
CD34, CD4, HLA-DR –ve
Jin et al. (2020) Human MSCs derived from bone marrow aspirate
from the ilium of healthy subjects
Cultured to third to fifth passage with
media changed every 48 h
Trilineage differentiation. Flow cytometry:
CD29, CD44, CD71 +ve. CD34, CD45,
and HLA-DR -ve
arefers to individual culture condition protocol without addition of stimulating factors.
embryonic stem cells (Zhang et al., 2016, 2018, 2019). Three
studies obtainedMSCs from bone marrow aspirate (Khatab et al.,
2018; Mao et al., 2018; Jin et al., 2020), one from infrapatellar fat
pad (Wu et al., 2019) and one from synovial tissue (Tao et al.,
2017). One study compared EVs from Induced Pluripotent Stem
Cell (iPS)-derived MSCs with synovium-derived MSCs (Zhu Y.
et al., 2017). All MSCs were characterized using flow cytometry
and trilineage differentiation. All MSCs expressed either CD44,
CD90 or CD105, and most expressed low levels of HLA-DR.
EV Characteristics
Ultracentrifugation and ultrafiltration were the two most
common methods for isolation of exosomes (Table 2). One
study used polyethylene glycol precipitation as part of the
purification process (Wu et al., 2019), and several used tangential
flow filtration (TFF). EV dimensions were determined using
Transmission Electron Microscopy (TEM) in all but one study
(Khatab et al., 2018). EV size ranged from 30 to 200 nm, with
a modal mean size of around 100 nm. Flow cytometry and
western blotting were standard methods for characterizing EVs.
CD9, CD63, CD81, and ALIX were the most common EV
markers identified. Five out of 10 studies that determined the
bioactive component of the EVs used with Reverse Transcriptase
quantitative Polymerase Chain Reaction (RT-qPCR) or Western
blot analysis. Three studies attributed the effects of EVs to various
miRNA. Two studies determined that CD73-mediated protein
kinase activation was responsible for the in vivo effects of EV
transplantation (Zhang et al., 2018, 2019).
Animal Models
All studies used murine models; five studies induced
osteoarthritis, including cartilage loss through surgical joint
destabilization, two studies directly created osteochondral
lesions and three studies used collagenase to cause cartilage
loss. All but one study, which examined the TMJ, studied the
knee joint. Follow-up duration ranged from 3 to 12 weeks
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TABLE 2 | Method of EV purification and characterization.
References Purification process EV dimensions EV marker Imaging Active component
Khatab et al. (2018) Ultracentrifugation Not determined Not determined Not utilized Not determined






Tao et al. (2017) Not specified 30–150 nm CD63, CD9,
CD81, ALIX
TEM, DLS Not determined
Wang et al. (2017) Ultracentrifugation 30–200 nm CD63, CD9 TEM Not determined








MiR-100-5p (targeting 3’UTR of
mTOR)
Zhang et al. (2016) Culture media concentrated by Tangential
Flow Filtration (TFF) sequentially through
membranes (1,000 kDa, 500 kDa, 300









Zhang et al. (2018) Conditioned medium was size fractionated








activation of MAPK signaling
Zhang et al. (2019) Conditioned medium was sized






TEM CD73 mediated activation of
MAPK signaling









TEM, TRPS Not determined
Jin et al. (2020) Conditioned media extracted using size
fractionation and filtration
50–100 nm CD63, CD9,
Hsp70
TEM miR-26a-5p
after induction of cartilage injury. All studies delivered EVs via
intra-articular injection. No significant side-effects were reported
in any subjects. Varying amounts of EVs were used between
studies, and the amount was quantified using different measures
(Table 3). Some studies injected a given volume with a known
concentration of EVs, whereas others determined the mass of
EVs delivered.
In vivo Findings
Two studies measured pain scores and one conducted
gait analysis following treatment with EVs, and all three
showed improved functional scores. Zhang et al. (2019) used
Micro-Computed Tomography (micro-CT) to assess cartilage
morphology and found improved bone integrity from 8 weeks
onwards. Gene-expression analysis undertaken in several studies.
Mao et al. reported increased chondrogenic gene regulation after
EV treatment. Using PCR, Zhang et al. (2019) and Jin et al.
detected reduced regulation of pro-inflammatory cytokines in
their studies.
Joint appearance was interrogated macroscopically,
microscopically or using both approaches. All studies reported a
reduction in cartilage loss after treatment with EVs. Microscopic
histological analysis focused on assessing cartilage thickness and
cartilage matrix appearance. Four studies conducted subjective
quantification of appearance using the OARSI score. All studies
found improved cartilage appearance or OARSI score in the
treated groups, although Khatab et al. reported no treatment
effect on subchondral bone volume at 3 weeks. Immunohistology
was utilized in all studies and all reported increased collagen
type II staining with several groups reporting reduced MMP3
immunostaining. Three studies reported reduced staining of
apoptotic markers.
Quality of Studies
The SYRCLE tool was used to grade each study using 15 different
parameters. Seven out of the 10 studies had a low level of concern
overall and three studies had some concern toward risk of
bias (Table 4). Blinding and detection bias constituted the main
contributors to bias in the studies. There was little selection and
reporting bias among the studies, but randomization of subjects
were not mentioned inmost studies. Overall, the studies included
in this review were of high quality and low risk of bias.
DISCUSSION
All 10 studies in this review reported reduced cartilage loss
following treatment with MSC-EVs. A variety of outcome
measures were employed in each study to examine the impact
of EVs on cartilage loss, but not all studies found improvements
in every parameter measured. A total of 159 subjects were





























TABLE 3 | Summary of findings from in vivo experiments.




Imaging and histology Biochemical analysis
Khatab et al. (2018) Intra-articular injection of
secretome (Derived from
20,000 third passage MSCs
suspended in 6 µl medium)




21 days Greater pain reduction in




thickness but no treatment
effect on subchondral bone
volume
Immunostaining of iNOS,




Mao et al. (2018) Intra-articular injection of 15
µl of MSC-derived exosomes
or MSC-derived exosomes
from a group pre-treated with
miR-92a-3p-Exos On days 7,
14, and 21





aggrecan staining in treated
lesions. Increased regulation
of WNT5A, COL2A1, and
aggrecan mRNA expression
Tao et al. (2017) Intra-articular injection of 100
µl of 1011 exosome
particles/mL weekly from
week 5 to 8 post-surgery
Murine, medial meniscus, and
medial collateral ligament
transection
12 weeks Not undertaken Histology: Less joint wear and






II collagen (Col II), aggrecan,
and type I collagen expression
Wang et al. (2017) Intra-articular injection of 5 µl
of exosomes into Knee joint at




8 weeks Not undertaken Improved OARSI score in
treated group. Reduced
microscopic appearance of
OA in treated group
Greater Col II staining and
weaker ADAMTS5 staining in
the treated group
Wu et al. (2019) Intra-articular injection of 10 µl
of exosome (1010 particles/ml)
weekly or biweekly
Murine, DMM 8 weeks Improved gait; increased weight
bearing on OA knee, swing speed
and intensity in treated groups
Improved OARSI score in the
treated group
Immunohistology showed
increased Col II expression,
decreased ADAMTS5 and
MMP13 expression.
Zhang et al. (2016) Intra-articular injection of 100




trochlear grooves of distal
femur
12 weeks Macroscopic: Moderate
improvement at 6 weeks,
near-complete neotissue coverage
and integration with surrounding
cartilage at 12 weeks in treated
groups. Improved International
Cartilage Repair Society (ICRS)
score at 12 vs. 6 weeks
Histology: smooth cartilage in
five out of six treated defects
at 12 weeks
Immunohistochemistry:
intense GAG staining (>80%),
high level of T2Col and low
level of T1Col in treated
lesions. Lubricin +ve cells
found in superficial and
middle zones of neo-cartilage
Zhang et al. (2018) Intra-articular injection of 100




trochlear grooves of distal
femur
12 Weeks Improved Wakitani macroscopic




Increased GAG and T2Col
staining in treated groups.
Increased Proliferative Cell
Nuclear Antigen (PCNA) and
decreased Cleaved
Caspase-3 (CCP3) at 12


























































































TABLE 3 | Continued




Imaging and histology Biochemical analysis
Zhang et al. (2019) Intra-articular injection of 100
µg of exosomes at weekly






(TMJ) by inject of
Monosodium iodoacetate
(MIA) into upper compartment
of the joint bilaterally
12 weeks Reduced Pain behavior in exosome
treated rats from 2 weeks onwards
as indicated by higher Head
Withdrawal Threshold (HWT) as





from 8 weeks post treatment
Histology: Improved Mankin
score in treated groups at 4
weeks onwards
Immunohistochemistry:
Increased GAG and T2Col
staining in treated groups.
Increased Proliferative Cell
Nuclear Antigen (PCNA) and
decreased Cleaved
Caspase-3 (CCP3) at 12
weeks in treated groups.
PCR: reduced expression of
IL-1B, BAX, alpha-SMA) and
Substance P, Nerve Growth
Factor (NGF), Tyrosine




Zhu X. et al. (2017) Intra-articular injection with 8
µl (1010/ml) of exosomes on
day 7,14, and 21 following OA
induction
Murine, CIOA 4 weeks Improved ICRS score in both iMSC
and sMSC group compared with
OA group at endpoint




improvement in OARSI score
than sMSC
Greater Col II staining in
treated groups. Greater Col II
staining in iMSC compared to
sMSC groups
Jin et al. (2020) Intra-articular injection of 250





ligament, medial and lateral
meniscus transection
8 weeks Not undertaken Improved microscopic
appearance, greater synovial
cell infiltration and fibrous
tissue formation in treated
groups
Reduced MMP-3 and
MMP-13 expression in treated
group. Reduced synovial cell
apoptosis in treated group.













































































































































































































































































































































































































































































































































































































































































































































































































































treated with MSC-EVs without significant or immunogenic
complications. While all the MSC-EVs were derived from human
MSCs, the subjects were all animal models of cartilage injury,
and therefore only indirectly inform safety and effectiveness in
human subjects.
The capacity forMSCs to expand ex vivo varies with cell source
(Fazzina et al., 2016) and anatomical site (Davies et al., 2017).
The ability of MSCs to undergo chondrogenic differentiation also
appears to differ between cell source (Bernardo et al., 2007). The
source of EVs varied significantly between studies as the MSCs
were harvested from different tissues and anatomical donor sites.
The influence of MSC source on the chondrogenic potential of
EVs remains unclear, with some studies suggesting that certain
MSC-EVs reduce type I and III collagen production (Li et al.,
2013). There is evidence that the biological properties of EVs
are dependent on MSC source (Kehl et al., 2019) and it is also
apparent that certain MSCs, for example those derived from
amniotic fluid, may produce a greater number of EVs than
bone marrow-derived MSCs when controlled for cell number
(Tracy et al., 2019). In this review, two studies used MSCs from
immortalized cell lines (Zhang et al., 2018, 2019) this provides
an advantage over autologous harvest as it is not invasive.
Zhu et al. compared iPS-derived MSC-EVs with sMSC-derived
EVs and found the former to be superior in cartilage repair.
Relative cost and convenience of production will dictate which
of these is favorable. These are important considerations in tissue
engineering as the optimal source cell should achieve a balance
between ease of harvest and acceptable EV production. MSC-
EV bioactivity also appear to depend on cell-culture conditions,
for example, the anti-apoptotic effects of adipose-derived MSC
secretome can be affected by oxygen tension (An et al., 2015).
Therefore, future studies will be required to delineate the
relationship between MSC cell source and secretome in order to
select the best source for optimal large-scale EV production.
Most studies in the literature examining EV function, in line
with our findings, use ultracentrifugation as the main component
of the isolation procedure (Gardiner et al., 2016). There is
evidence that suggests that ultracentrifugation could increase
the amount of contamination by macromolecules within the
MSC culture media (Webber and Clayton, 2013). This may be
of relevance in our interpretation as MSC-conditioned media
is known to contain non-vesicular bioactive components that
may promote chondrogenesis (Chen et al., 2018) and lead
to an overestimation of EV effectiveness in cartilage repair.
While this may make comparisons difficult, the augmented
repair is not necessarily an undesired effect. Furthermore, while
the effect of multiple washing stages that form part of the
centrifugation process improves purity, it may decrease the total
number of EVs obtained (Webber and Clayton, 2013) TFF was
the next most commonly used method of concentrating EVs.
Compared to ultracentrifugation, TFF achieves a greater EV
yield, with a reduced amount of non-vesicular macromolecules
contamination (Busatto et al., 2018). Other forms of flow-based
purification such as Cross-flow isolation are also favorable over
ultracentrifugation in terms of rate of production at large scale
(McNamara et al., 2018). Ultimately, robust cost-effectiveness
studies may be required to determine the optimal method
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of purification. The transferability of this review may also be
limited by the inconsistent methodologies used by the studies
to characterize the EVs used. Apart from one study that did not
report on any EV markers (Khatab et al., 2018), all other studies
identified markers recognized by the Minimal Information for
Studies of Extracellular Vesicles (MISEV) criteria (Théry et al.,
2018). EV dimensions were found to range from 30 to 200 nm.
The range of 50–150 nm was most commonly reported and may
reflect the bias of measurement devices. Future studies should
attempt to ascertain the main peak value within the detected
range as Wu et al. (2019) did in their study.
Whilst all studies directly injected EVs intra-articularly, the
dose delivered was highly varied. Although EV transplantation
is yet to be tested in clinical studies, proof-of-concept human
clinical trials of intra-articular injection of MSCs to treat cartilage
lesions demonstrate a dose-dependent effect without increased
risk of adverse effects (Jo et al., 2014). Similar studies will be
required to establish such a relationship for EV transplantation.
In MSC treatment of cartilage lesions, intra-articular injection
appear to promote good engraftment rates with minimal off-
site engraftment (Satué et al., 2019). In in vivo studies of
anterior cruciate ligament repair, intravenous injection of MSCs
concomitantly with intra-articular injection produced improved
outcomes (Muir et al., 2016). Likewise, intravenous EV injection
appear to produce a dose-dependent immunosuppressive effect
that may be beneficial for treating arthritis (Cosenza et al., 2018),
but the effect on cartilage repair remains unknown, and the
potential for off-site engraftment of EVs is not yet characterized.
All animal studies to date on human-derived MSC-EVs have
focussed on murine models. Articular cartilage repair can be
studied in murine models in several ways. Firstly, the joint may
be surgically destabilized such as in destabilization of medial
meniscus (DMM) models, leading to altered weight-bearing and
subsequently generalized OA changes, which includes cartilage
loss. These models are reliable, reproducible, and have high
disease penetrance. The time-course over which cartilage changes
develop is delayed and therefore recapitulates the nature of
human disease (Glasson et al., 2007). Cartilage can also be
excised surgically through induction of an osteochondral defect.
These defects may progress at different rates depending on the
operative site (Haase et al., 2019), and so makes for difficulty
in determining the optimal timing of EV treatment. In contrast,
DMMmodelsmay progress to display cartilage loss at time points
later than direct osteochondral injury and therefore may not
benefit from EV treatment in the acute post-injury phase. The
amount of lesion healing however appeared to be similar when
comparing findings from Zhang et al. (2016) and Zhang et al.
(2018), where the same treatment was given after DMM and
direct osteochondral injury, respectively. Cartilage loss may also
be induced using enzymes or chemicals that degrade the cartilage.
Three studies induced chondral injury in murine models using
collagenase and one study used monosodium iodoacetate (MIA).
Chemical induction is less predictable and may also attenuate
the effects of cell-based therapies mimicking its effects on tissue-
native cells (Taghizadeh et al., 2018). One study focused on
the temporomandibular joint (TMJ). As the pathoaetiology and
epidemiology of these non-weight bearing joints typically differ,
with radiographic TMJ cartilage loss often being asymptomatic
(Schmitter et al., 2010), it may not be relevant to compare
functional outcomes following treatment.
It is important to determine standardized methods of
assessing outcomes relevant to cartilage repair. Several studies
reported improvements in the macroscopic appearance of
cartilage; while macroscopic appearance scoring is predictive
of histological scoring (Goebel et al., 2017), it is unclear
how this correlates with functional improvements. The three
studies that used collagenase to induce cartilage loss, often
termed collagenase induced OA (CIOA) models, assessed the
highly clinically relevant outcomes of pain behavior, with both
reporting reduction from early stages. It is difficult to draw
conclusions from these results as cartilage loss and eventual
OA in the murine model is typically late in onset and
appears over 10 weeks following injury (Inglis et al., 2008).
It is encouraging however, that all studies reported improved
microscopic cartilage repair, with several studies employing
various subjective quantitative scoring systems (Tao et al., 2017;
Wang et al., 2017; Zhu Y. et al., 2017; Wu et al., 2019). It may
be informative to conduct a pooled analysis of such outcomes,
but it is unlikely to be meaningful in this study owing to the
heterogeneity in scores used. Not all studies reported favorable
outcomes when assessing markers of cartilage repair. Khatab
et al. conducted an immunohistochemical analysis of iNOS
and CD206 expression which are markers of inflammation and
M2 macrophage, respectively (Fahy et al., 2014), and found
no difference between the groups at the end of the study.
Inflammation probably attenuates cartilage repair by interfering
with chondrocyte activity and so could be of greater relevance in
the acute stage (Tung et al., 2002). Themajority of studies showed
improved collagen immunostaining, and greater expression of
chondrogenic genes in tissue samples. Several groups evaluated
cell apoptosis as an outcome and found decreased expression of
markers of apoptosis following treatment (Zhang et al., 2018; Jin
et al., 2020). Indeed, chondrocyte apoptosis may be reflective of
matrix depletion in the cartilage (Kim et al., 2001).
In addition to promoting chondrogenesis in chondrocytes, it
is likely that EVs contribute to cartilage repair via effects on other
cell types. Macrophages are postulated to be a key target forMSC-
EVs, with evidence suggesting that EVs cause an M2 phenotype
polarization that promotes resolution of inflammation and so
promotes cartilage repair (Chen et al., 2019). This notion is
supported by the fact that macrophages pre-conditioned with
MSC-EVs, termed EV-educated macrophages (EEMs) support
tendon healing in vivo to a greater extent than treatment with
MSC-EVs alone (Chamberlain et al., 2019). Others suggest that
MSC-EV secretome actually augments the immunomodulatory
effects of MSCs via autocrine action. It appears that IL-1β-
pretreated MSCs induce macrophages into an anti-inflammatory
phenotype only when in the presence of EVs containing miR-
146a (Song et al., 2017). Transplantation of circulating EVs from
septic mice however, appear to encourage neutrophil migration
and macrophage inflammation; this is attributed to certain
miRNAs including miR-126-3p, miR-222-3p, and miR-181a-5p,
suggesting that EV-dependent modulation of inflammation is
content and context dependent (Xu et al., 2018). Further to this,
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caution should be exercised with MSC-EV transplantation in
certain patient cohorts, as MSC-EV have been shown to attenuate
the ability of macrophages to suppress cancer cells, and in doing
so promotes tumorigenicity (Ren et al., 2019).
CONCLUSION
Due to the plethora of pathways through which MSC-EVs can
promote cartilage repair, a key step to studying their effects
in animal models is to establish the roles of the different
bioactive components within EVs. Similarly, outcome measures
utilized in studies should complement this. We recommend
that cartilage appearance and chondrogenic gene expression
should be primary outcomes in addition to quantifiable and
clinically relevant functional outcomes such as pain reduction
or animal gait analysis. Likewise, it would be beneficial to
establish a link between functional and histological outcomes,
as the value of assessing histology may otherwise be minimal.
In order to establish the optimal way to deliver clinical benefit
usingMSC-EVs, themost efficientMSC cell source, methodology
of cell culture and EV purification should be investigated
for the purposes of cartilage repair. Finally, randomized
studies in animal models that recapitulates the human disease
will be necessary in order to establish a dose-response
relationship and therefore clinical safety before we proceed to
human trials.
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